Update shared on06 Aug 2025
Fair value Decreased 41%Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations.
What's in the News
- SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.
- Y-mAbs presented an overview of its Phase 1 trial for GD2-SADA pretargeted radioimmunotherapy in high-risk neuroblastoma and other GD2-expressing solid tumors at the Advances in Neuroblastoma Research Meeting.
- The company reaffirmed Q2 and full-year 2025 revenue guidance, expecting $17–19 million for the quarter and $75–90 million for the year.
Valuation Changes
Summary of Valuation Changes for Y-mAbs Therapeutics
- The Consensus Analyst Price Target has significantly fallen from $14.70 to $11.68.
- The Future P/E for Y-mAbs Therapeutics has significantly fallen from 68.93x to 47.56x.
- The Net Profit Margin for Y-mAbs Therapeutics has significantly risen from 10.54% to 12.26%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.